Skip to main content

Table 1 Patient and tumor characteristics

From: Prognostic impact of immune gene expression signature and tumor infiltrating immune cells in localized clear cell renal cell carcinoma

Characteristic UAB discovery dataset Fox chase validation dataset
Number (N = 159), % Recurrers (N = 33), % Number (N = 198), % Recurrers (N = 53), %
Median Age 58 59 61 59
Gender
 Female 60 (37.8) 11 (33.3) 55 (27.7) 13 (24.5)
 Male 99 (62.2) 22 (66.7) 143 (72.2) 40 (75.4)
Race
 Caucasian 124 (77.9) 30 (90.9) 190 (96) 51 (96.2)
 AA 19 (12.0) 2 (6) 6 (3.0) 2 (3.7)
 Other 16 (10.1) 1 (3) 2 (1) 0 (0)
Median Follow-up 48.3 mo (24.5–120.5) 56 mo (25.5–119.7) 70.92 (15.4–126.9) 61.9 mo (16.2–126.9)
Median time to recurrence   25.8 mo (4.2–114.7)   18.4 mo (2.3–85.3)
Pathologic T stage
T1 / T2 / T3/ T4 62 / 20 / 77 / 0(38.9 / 12.6 / 48.5) 4 / 6 / 23 / 0 (12.1 / 18.1 / 69.7) 89 / 31 / 76 / 2 (45 / 15.6 / 38.3 / 1) 17 / 6 / 28 / 2 (32 / 11.3 / 52.8 / 3.7)
Grade
 1–2 43 (27) 6 (18.1) 58 (29.2) 9 (16.9)
 3–4 116 (73) 27 (81.8) 140 (70.7) 44 (83)
Necrosis
 Yes 48 (30.2) 18 (54.5) 61 (30.8) 28 (52.8)
 No 111 (69.8) 15 (45.4) 137 (69.1) 25 (47.1)
Lymphocyte infiltration scoring
 0 10 (6.2) 0 (0) 27 (13.6) 5 (9.4)
 1 56 (35.2) 7 (21.2) 44 (22.2) 10 (18.9)
 2 30 (18.8) 9 (27.2) 48 (24.2) 9 (17)
 3 33 (20.7) 7 (21.2) 31 (15.6) 10 (18.9)
 4 30 (18.8) 10 (30.3) 48 (24.2) 19 (35.8)